1. Antibody-drug Conjugate/ADC Related
  2. Drug-Linker Conjugates for ADC
  3. Mipsagargin

Mipsagargin (G-202) 是一种基于毒胡萝卜素的新型靶向前体,由前列腺特异性膜抗原 (PSMA) 特异性肽与强效肌浆/内质网钙腺苷三磷酸酶 (SERCA) 泵抑制剂毒胡萝卜素 (HY-13433) 的类似物偶联而成。Mipsagargin 可以被 PSMA 介导的惰性掩蔽肽裂解激活。Mipsagargin 具有用于难治性、晚期或转移性实体瘤研究的潜力。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Mipsagargin Chemical Structure

Mipsagargin Chemical Structure

CAS No. : 1245732-48-2

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research[1][2][3].

IC50 & Target[1]

Traditional Cytotoxic Agents

 

体外研究
(In Vitro)

Mipsagargin (G-202) 作用于不产生 PSMA 的 TSU 细胞 (IC50=191 nM),是产生 PSMA 的 LNCaP 细胞的 57 倍 (IC50=5351 nM)[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Mipsagargin (G-202; 56 mg/kg; 静脉给药; 每天 2 次; 49 天) 单独能够产生显着的肿瘤消退 (>50%)。当同时每日服用口服 HDAC4 抑制剂 Tasquinimod (HY-10528) 时,这种趋势得到稳定[1]
Mipsagargin (56 mg/kg/天; 静脉给药; 连续 3 天) 在 30 天的时间内使完整小鼠的 LNCaP 异种移植物平均消退约 50%。在 Mipsagargin 的一个 3 天疗程后,针对 MDA-PCa2b 和 CWR22R-H 的显着抗肿瘤作用也观察到了长达 ≥ 30 天[2]
Mipsagargin (67 mg/kg; 静脉给药) 在 BALB/c 小鼠中的半衰期为 4.9 小时[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MCF-7 human breast cancers growing in mice[1]
Dosage: 56 mg/kg
Administration: IV; 2 daily; 49 days
Result: Alone was able to produce significant (>50%) tumor regression.
This regression was stabilized when combined with daily dosing with the oral HDAC4 inhibitor, Tasquinimod (10 mg/kg/d; oral).
Animal Model: BALB/c mice[2]
Dosage: 67 mg/kg (Pharmacokinetic Analysis)
Administration: IV; a single dose
Result: Had a half-life of 4.9 hours.
Clinical Trial
分子量

1409.52

Formula

C66H100N6O27

CAS 号
Sequence

Asp-{Ggu}-{Ggu}-{Ggu}-{Ggu}

Sequence Shortening

D{Ggu}-{Ggu}-{Ggu}-{Ggu}

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Mipsagargin
目录号:
HY-16215
需求量: